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Abstract
Eosinophilic esophagitis (EoE) is an increasingly recognized disorder whose diagnosis is based on histologic
demonstration of eosinophilic inflammation. We previously reported improvement of symptoms in children with EoE
on long-term proton-pump inhibitor (PPI) monotherapy despite persistent eosinophilic inflammation. We sought to
determine whether PPI monotherapy in children with EoE is associated with decreased eosinophil degranulation.
Ten children with EoE had esophageal biopsies assessed for eosinophil, mast cell and Langerhans cell
concentration and eosinophil degranulation at diagnosis and following PPI treatment. There was no significant
difference in cell concentrations between initial and one-year follow-up. A significant decrease in number of free
lying granules was observed at the one-year follow-up biopsies. Prolonged PPI therapy in EoE is associated with
decreased eosinophil degranulation.

Keywords: Eosinophilic esophagitis; Proton-pump inhibitors;
Degranulation

Introduction
Eosinophilic esophagitis (EoE) is an increasingly recognized
disorder. Diagnosis of EoE is based on histologic demonstration of
eosinophilic inflammation, with ≥15 eosinophils per high power field
(hpf) being the cutoff most commonly used, in the absence of
pathologic reflux as evidenced by a normal pH monitoring study or
persistent inflammation on high-dose proton pump inhibitor (PPI)
treatment [1]. Symptoms include feeding issues, vomiting, chest or
abdominal pain, dysphagia and food impaction [2].
Eosinophils contain multiple toxic granules, whose content include
basic proteins, cytokines, chemokines, lipid mediators, and oxygen
radicals. Free-lying granules serve as a surrogate marker for released
eosinophil products that promote tissue damage, inflammation,
remodeling, and fibrosis [3]. Eotaxin-3 is a chemokine stimulated by
T-helper cytokines to recruit and activate eosinophils. PPI’s have been
shown to block eotaxin-3 release, suggesting a role independent of acid
production [4]. We previously reported improvement of symptoms in
children with EoE on long-term PPI monotherapy despite persistent
eosinophilic inflammation [5]. We hypothesized that symptomatic
improvement in our patients was due to a PPI effect in eotaxin 3induced degranulation. Therefore, we sought to determine whether the
improvement with PPI monotherapy was associated with decreased
eosinophil degranulation.

Methods
We reviewed the records and biopsies from ten patients previously
described [5] with EoE who improved clinically on PPI monotherapy.
All patients were between 1 month and 18 years old, were on an
unrestricted diet, were diagnosed with EoE based on standard criteria
[1] with persistence of eosinophils on follow-up biopsies 3 months
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after diagnosis while on PPI, and had undergone follow-up endoscopy
at least one year after diagnosis.
Hematoxylin and eosin-stained sections were reproduced from
formalin
fixed
paraffin-embedded,
endoscopically-obtained
esophageal biopsies and evaluated to quantify eosinophils and assess
degranulation. Immunohistochemical staining with tryptase for mast
cells, and S100 for Langerhans cells using standard methodology was
performed to evaluate their presence and possible role in eosinophil
recruitment.
Using 400X magnification, all intraepithelial eosinophils were
counted in three separate fields that had the highest density of
eosinophils in each slide. The average number of eosinophils for these
three fields was reported. The same method was used to quantify mast
cells (tryptase) and Langerhans cells (S-100).
Using 600X magnification, areas with the highest concentration of
scattered eosinophil granules were photographed using a Nikon
Digital Sight DS-Fi1 microscope camera. Each image was printed on
standard short bond paper (21.5 cm x 28 cm, representing a
microscopic field of 7752 µm2). A 5.3 cm x 6.8 cm rectangular frame
(corresponding to a microscopic area of 1938 µm2) was used to
designate the areas with the highest density of free-lying eosinophil
granules. All free-lying granules within this framed area in three
separate fields were counted, and the mean was reported.

Statistics
Comparison of results between presentation and most recent
endoscopy was performed using paired t-test. Results are expressed as
mean ± SD.
This study was reviewed and approved by the Institutional Review
Board of the North Shore - LIJ Health System.
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Results

Comparison between proximal and distal esophageal
biopsies

Demographics
The mean age of the patients was 6.6 ± 4.8 years with 7 males.
Presenting complaints were dysphagia (4), failure to thrive (3),
abdominal pain (1) and vomiting (2). The patients had a second
follow-up biopsy 17.1±8.5 months following initiation of PPI. The
mean PPI dose was 1.5 ± 0.6 mg/kg. Nine patients were treated with
lansoprazole and one child with esomeprazole. All patients were either
asymptomatic (n=9) or significantly improved (n=1) on PPI
monotherapy.

Comparison between biopsies at diagnosis and follow-up on
PPI therapy
There was no significant difference in eosinophil count between
initial and follow-up endoscopies. Compared to the initial endoscopy,
the granule count decreased by the 3-month follow-up endoscopy and
significantly decreased by the 1-year follow-up (Table 1).
Mean ± SD

p value*

Eosinophils/hpf

There was no statistically significant difference in eosinophil
number between proximal and distal biopsies for all endoscopies.
There was no difference in granule number between proximal and
distal biopsies on the initial and 3-month follow-up endoscopies.
However, at the 1-year follow-up endoscopy, the granule number in
the proximal biopsy (50.8±41.8) was significantly increased compared
with the distal biopsy (25.1±28.7, p<0.05, Table 2).
Proximal
esophagus
(mean ± SD)

Distal
esophagus

Initial endoscopy

139.2±84.2

151.0 ± 10.5

p=NS

3-month
endoscopy

61.4 ± 30.2

46.0 ± 41.7

p=NS

One
year
50.8 ± 41.8
endoscopy

25.1 ± 28.7

p<0.05

p value

(mean ± SD)

Table 2: Granule counts in proximal and distal esophagus.

Discussion

Initial endoscopy

106.2 ± 38.6

3-month endoscopy

76.7 ± 60.1

NS

One-year endoscopy

67.6 ± 75.6

NS

Granule count
Initial endoscopy

105.5 ± 58.1

3-month endoscopy

72.0 ± 28.2

NS

One- year endoscopy

48.7 ± 43.3

p<0.05

Mast cells/hpf
Initial endoscopy

6.4 ± 12.9

3-month endoscopy

3.4 ± 2.7

NS

One- year endoscopy

4.7 ± 5.7

NS

Langerhans cells/hpf
Initial endoscopy

3.7 ± 2.5

3-month endoscopy

6.8 ± 3.5

p<0.01

One- year endoscopy

5.5 ± 2.1

NS

Table 1: Comparison of histological markers in Eosinophilic
Esophagitis. *p values are comparing 3-month and 1-year endoscopy
to initial endoscopy.
Compared to initial endoscopy, the mast cell number was not
different at the 3-month or 1-year follow-up endoscopy. The
Langerhans cell number was increased at the 3-month follow-up
endoscopy, but was not significantly different from the initial
endoscopy at the 1-year follow-up (Table 1).

Our case series suggests that children diagnosed with EoE treated
with PPI monotherapy for at least one year have decreased eosinophil
degranulation despite persistent eosinophilic inflammation. The
persistence of eosinophils in these patients is not surprising since the
criteria used for diagnosing EoE is lack of histologic response to PPI
therapy. However, the finding of decreased degranulation despite the
persistence of eosinophilic inflammation with only PPI therapy has
not been previously described.
The decline in granules and improvement in symptoms may be due
to an effect of PPI on eosinophil function. Zhang et al. [4]
demonstrated that omeprazole significantly inhibited IL-4 stimulated
eotaxin-3 protein secretion and m-RNA expression in EoE esophageal
cells. Eotaxin-3 is known to be a potent eosinophil chemoattractant,
but it also plays a role in activation and degranulation of eosinophils
[4]. Although the studies suggest that PPI has an in-vitro effect [4] as
well as a clinical benefit [5] in EoE, our current study is the first to
associate the clinical improvement with the decrease in eosinophil
degranulation. Reduced eosinophil degranulation after PPI is a
morphologic finding that correlates with reduced eotaxin secretion.
One of the novelties of the current paper lies in the fact that it provides
a morphologic correlate of the biochemical findings, and allows a
visual window into the mechanism involved. It is likely that eosinophil
degranulation contributes to clinical symptoms, perhaps by inducing
inflammation and fibrosis [3]. Although our patients who were
clinically well still had some degree of free-lying esophageal granules,
the significant decrease in granule number suggests that the lesser
degree of degranulation is the factor leading to the clinical
improvement. The lack of effect of PPI therapy on eosinophil number
in our study may reflect the fact that eotaxin-3 may have a quicker or
earlier effect on eosinophil degranulation than recruitment, and that
longer PPI treatment may eventually lead to decreased tissue
eosinophilia.
We noted that the granule number in distal biopsies at 1-year
follow-up was significantly more decreased than the granule count in
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proximal biopsies. It is known that patients with EoE have dysmotility
[2] which may predispose them to reflux-induced disease. One may
postulate that the acid-suppressive effect of PPI contributes to
improvement in eosinophil degranulation noted in the distal biopsies.
The inflammatory cascade may play a role in EoE [2]. In this study,
we found that the mast cell number did not differ between initial and
follow-up endoscopies in the EoE group. Langerhans cells were
increased at the 3-month biopsy compared with the initial biopsies;
however, the numbers were not different between initial and 1-year
biopsies.
Eosinophils contain many different toxic granules and it is unclear
which specific granule is responsible for the inflammation, remodeling
and fibrosis seen in EoE. Free-lying granules serve as a surrogate
marker for all released eosinophil products. Therefore, in this study we
did not attempt to identify the specific protein seen within the released
granules.
This paper examines the extracellular localization of the eosinophil
granules in the epithelium, not the protein content of the granules.
The tinctural properties of these granules are stable after fixation.
Although formalin fixation may theoretically have an effect on
eosinophil degranulation at the moment the tissue is placed into
formalin, all tissues were treated the same way. Once embedded in
paraffin the tissues are stable in a state of "suspended animation"
reflecting their morphology at the time of fixation. Degranulation
cannot occur once the tissue is embedded in paraffin.
The patients studied were all maintained on a regular unrestricted
diet, and therefore, any differences could not be due to changes in
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dietary exposure. The patients in our EoE group are distinct from
those patients who are thought to have a newly described entity called
PPI-responsive esophageal eosinophilia. In that group, patients have
increased esophageal eosinophilia but respond histologically to PPI
monotherapy [1].
Prospective studies are needed to confirm our findings, to evaluate
the precise mechanism in which PPIs decrease eosinophilic
degranulation, and the role granules play to explain symptomatic
improvement.
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